Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This observational study will assess the safety of Herceptin (trastuzumab) in patients with HER2-positive breast cancer in routine clinical practice. Eligible patients will be followed for up to 4 years.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Safety: Incidence of adverse events | up to approximately 4.5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of symptomatic congestive heart failure (NYHA class II, III and IV) | up to approximately 4.5 years | |
| Incidence of asymptomatic LVEF decline | up to approximately 4.5 years | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with HER2-positive breast cancer eligible for treatment with Herceptin
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Algiers | 16000 | Algeria | ||||
Not provided
Not provided
Not provided
Not provided
| Frequency of treatment discontinuations/interruptions |
| up to approximately 4.5 years |
| Annaba |
| 23000 |
| Algeria |
| Blida | 9000 | Algeria |
| Mascara | 29000 | Algeria |
| Oran | 31000 | Algeria |
| Sidi Belabes | 22000 | Algeria |
| Tizi Ouzou | 15000 | Algeria |
| Agadir | 80000 | Morocco |
| Casablanca | 20000 | Morocco |
| Casablanca | 20052 | Morocco |
| Casablanca | 20100 | Morocco |
| Casablanca | 20502 | Morocco |
| Casablanca | Morocco |
| Fes | 30000 | Morocco |
| Marrakesh | 40000 | Morocco |
| Rabat | 10000 | Morocco |
| Rabat | 21000 | Morocco |
| Rabat | 6213 | Morocco |
| Rabat | Morocco |
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided